Cassava Sciences Rebrands as Filana Therapeutics, Focusing on Filamin A for CNS Disorders

martes, 10 de marzo de 2026, 8:09 am ET1 min de lectura
SAVA--

Cassava Sciences is rebranding to Filana Therapeutics, Inc. and will begin trading under the ticker symbol "FLNA" on March 11, 2026. The name change reflects the company's focus on developing novel medicines to modulate filamin A for treating CNS disorders such as TSC-related epilepsy. The new corporate identity aims to center the company's identity on filamin A and its potential in treating CNS disorders.

Cassava Sciences Rebrands as Filana Therapeutics, Focusing on Filamin A for CNS Disorders

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios